KR20230047400A - 수성 조성물 - Google Patents

수성 조성물 Download PDF

Info

Publication number
KR20230047400A
KR20230047400A KR1020237005628A KR20237005628A KR20230047400A KR 20230047400 A KR20230047400 A KR 20230047400A KR 1020237005628 A KR1020237005628 A KR 1020237005628A KR 20237005628 A KR20237005628 A KR 20237005628A KR 20230047400 A KR20230047400 A KR 20230047400A
Authority
KR
South Korea
Prior art keywords
mass
aqueous composition
salts
acid
component
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020237005628A
Other languages
English (en)
Korean (ko)
Inventor
오조라 구보
사에코 하야시
아키코 기타
Original Assignee
로토 세이야쿠 가부시키가이샤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 로토 세이야쿠 가부시키가이샤 filed Critical 로토 세이야쿠 가부시키가이샤
Publication of KR20230047400A publication Critical patent/KR20230047400A/ko
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020237005628A 2020-07-30 2021-07-30 수성 조성물 Pending KR20230047400A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2020129728 2020-07-30
JPJP-P-2020-129728 2020-07-30
PCT/JP2021/028439 WO2022025279A1 (ja) 2020-07-30 2021-07-30 水性組成物

Publications (1)

Publication Number Publication Date
KR20230047400A true KR20230047400A (ko) 2023-04-07

Family

ID=80036428

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020237005628A Pending KR20230047400A (ko) 2020-07-30 2021-07-30 수성 조성물

Country Status (9)

Country Link
US (1) US20230285562A1 (https=)
EP (1) EP4176882A4 (https=)
JP (1) JPWO2022025279A1 (https=)
KR (1) KR20230047400A (https=)
CN (1) CN116568285A (https=)
AU (1) AU2021318236A1 (https=)
CA (1) CA3190310A1 (https=)
TW (1) TWI908843B (https=)
WO (1) WO2022025279A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024194105A1 (en) * 2023-03-17 2024-09-26 Leo Pharma A/S A method for the treatment of chronic hand eczema in patients with moderate to severe chronic hand eczema
WO2025032221A1 (en) * 2023-08-09 2025-02-13 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Jak-inhibitor for the treatment of ten, sjs and sjs/ten overlap
EP4506005A1 (en) * 2023-08-09 2025-02-12 Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. Jak-inhibitor for the treatment of ten, sjs and sjs/ten overlap

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017006968A1 (ja) 2015-07-07 2017-01-12 日本たばこ産業株式会社 ７Ｈ－ピロロ［２，３－ｄ］ピリミジン誘導体の製造方法及びその中間体

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2018229A1 (en) * 1970-04-16 1971-10-28 Ferrous sulphate stabilized with citric acid
CL2009001884A1 (es) * 2008-10-02 2010-05-14 Incyte Holdings Corp Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco.
KR102306276B1 (ko) * 2013-10-21 2021-09-30 니뽄 다바코 산교 가부시키가이샤 안질환의 치료제 또는 예방제
KR102702286B1 (ko) 2016-12-21 2024-09-04 니뽄 다바코 산교 가부시키가이샤 7H-피롤로[2,3-d]피리미딘 유도체의 제조 방법 및 그의 공결정
KR20220044288A (ko) * 2019-08-07 2022-04-07 로토 세이야쿠 가부시키가이샤 누액 분비 촉진용 안과 조성물
EP4674401A3 (en) * 2019-12-27 2026-02-25 Rohto Pharmaceutical Co., Ltd Container accommodating an aqueous ophthalmic composition comprising delgocitinib
US20230285564A1 (en) * 2020-07-30 2023-09-14 Rohto Pharmaceutical Co., Ltd. Aqueous Composition

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017006968A1 (ja) 2015-07-07 2017-01-12 日本たばこ産業株式会社 ７Ｈ－ピロロ［２，３－ｄ］ピリミジン誘導体の製造方法及びその中間体

Also Published As

Publication number Publication date
EP4176882A1 (en) 2023-05-10
TWI908843B (zh) 2025-12-21
TW202220658A (zh) 2022-06-01
EP4176882A4 (en) 2024-01-10
AU2021318236A1 (en) 2023-03-09
JPWO2022025279A1 (https=) 2022-02-03
US20230285562A1 (en) 2023-09-14
WO2022025279A1 (ja) 2022-02-03
CN116568285A (zh) 2023-08-08
CA3190310A1 (en) 2022-02-03

Similar Documents

Publication Publication Date Title
KR20230047400A (ko) 수성 조성물
JP6886502B2 (ja) アトロピン含有水性組成物
KR20230047401A (ko) 수성 조성물
JP6886878B2 (ja) ドルゾラミドとチモロールと界面活性剤を含有する医薬組成物
KR0159768B1 (ko) 안정한 주사용 수성 조성물 및 그러한 조성물의 안정화 방법
JP2025019313A (ja) 涙液分泌促進用眼科組成物
JP7722931B2 (ja) 水性組成物
WO2021132598A1 (ja) 水性組成物
JP2021100976A (ja) 水性組成物
KR20140139501A (ko) 2-아미노-3-(4-브로모벤조일)페닐아세트산 함유 수성 조성물
HK40091721A (zh) 水性组合物
HK40091389A (zh) 水性组合物
JP6817877B2 (ja) ドルゾラミド、高分子およびホウ酸を含有する医薬組成物
JP2019081801A (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
HK40004290B (en) Atropine-containing aqueous composition
HK40004290A (en) Atropine-containing aqueous composition
JP2016041749A (ja) シリコーンハイドロゲルコンタクトレンズ用眼科組成物
HK40003059B (zh) 含有阿托品的水性组合物

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20230217

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20240723

Comment text: Request for Examination of Application